Why do most combination trials omit component arms?

Cost and regulatory necessity. Component arms add participants without contributing to the placebo comparison a registration usually needs, and they create the possibility of a result the sponsor would rather not have. Including them is a choice that goes beyond the minimum requirement.

Is a 302-participant component arm useless?

No. It removes every cross-trial confounder from the comparison - same protocol, same sites, same period - which is far better than comparing against a different trial's arm. It is imprecise, not uninformative.

Does regulatory approval require this evidence?

For fixed-dose combinations of licensed drugs, evidence that each component contributes to the claimed effect is generally expected, and factorial or active-comparator designs are how it is supplied. The strength of that expectation varies by jurisdiction and by indication.

Can a meta-analysis substitute for component arms?

Only by indirect comparison, which requires assuming trials are exchangeable and is weaker than randomising within one trial. Where the within-trial arms exist, they are the better evidence.

GLP-1 & Incretin Science

The Randomisation Ratio Decides What a Trial Can Say

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-244 cited sources

A fixed-dose combination can only be shown to exceed its components if participants are randomised to those components in adequate numbers. Two trials of the same combination made opposite choices about that, and the difference determines what each can conclude.

Key facts

Question at issue: Does the combination beat its own components?
What it requires: Randomised arms receiving each component alone
REDEFINE 1 allocation: 21:3:3:7
REDEFINE 1 component arms: 302 each, against 2,108
REDEFINE 1 primary comparison: Against placebo
REIMAGINE 2 allocation: 8:8:2:8:8:1:1
REIMAGINE 2 head-to-head arms: 603 vs 605
REIMAGINE 2 primary comparison: Against semaglutide 2.4 mg

The question, stated precisely

A combination product contains two active components. Showing that it works is easy and uninformative, because at least one component works on its own. The question that determines whether the combination is worth having is narrower: does it do more than the better of its components alone? Answering that requires arms in which people receive the components separately, at the doses they occupy in the combination, under the same protocol - and it requires enough of them for the comparison to be precise.

Where the participants go is where the precision goes

Statistical precision in a two-arm comparison is governed by the smaller arm. Allocating twenty-one parts to a combination and three to a component does not produce a well-measured comparison between them; it produces a very well-measured combination arm and a roughly measured component arm, and the comparison inherits the roughness. This is why the allocation ratio in a multi-arm trial is not an administrative detail. It is a statement about which questions the trial intends to answer well, made before any data is collected.

Two trials, two answers to that

REDEFINE 1 randomised 3,417 participants 21:3:3:7 to the combination, semaglutide alone, cagrilintide alone and placebo - giving 2,108, 302, 302 and 705. Its co-primary endpoints are against placebo. REIMAGINE 2 randomised 2,713 participants 8:8:2:8:8:1:1 across six arms, giving 603 to the combination at the top dose and 605 to semaglutide at the matching dose, with the primary endpoint being the comparison between those two. Same combination, same components, opposite structural priorities.

Neither choice is wrong

REDEFINE 1's job was registration in obesity, where the required demonstration is superiority to placebo and where precision on that comparison is what a regulator asks for. Devoting most participants to the arm that has to be characterised for safety as well as efficacy is entirely reasonable, and including component arms at all - which most combination programmes do not - is more than the minimum. REIMAGINE 2's job was different: to establish added benefit over the component in a glycaemic indication where semaglutide is already the standard, which makes the active comparator the necessary primary. The point is not that one design is better but that the two support different claims, and the claims travel further than the designs do.

What this means for reading any combination result

Three questions settle most of it. Did anyone receive the components alone, in this trial? How many, relative to the combination arm? And was the comparison against a component a primary endpoint or an afterthought? If the answer to the first is no, the trial cannot speak to added benefit at all, however large its effect. If the answer to the second is a small fraction, the comparison exists but is imprecise. Only when a component comparison is both adequately sized and pre-specified as primary does a trial carry the weight that 'the combination is superior' implies.

The connection to fixed-ratio products generally

The same logic applies to any product supplying several actives in one preparation, including the research blends covered elsewhere in this library. The difference is that a pharmaceutical programme can run the component arms and sometimes does, whereas a fixed-ratio blend whose per-component split is undisclosed cannot be studied that way by anyone. REDEFINE 1 and REIMAGINE 2 are worth knowing about partly because they show what the answerable version of the question looks like when someone funds it.

Quick reference

	REDEFINE 1	REIMAGINE 2
Total randomised	3,417	2,713
Arms	4	6
Allocation	21:3:3:7	8:8:2:8:8:1:1
Combination arm	2,108	603
Matching component arm	302	605
Primary comparator	Placebo	Semaglutide 2.4 mg
Supports 'adds to the component'?	Weakly	Directly

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Why do most combination trials omit component arms?: Cost and regulatory necessity. Component arms add participants without contributing to the placebo comparison a registration usually needs, and they create the possibility of a result the sponsor would rather not have. Including them is a choice that goes beyond the minimum requirement.
Is a 302-participant component arm useless?: No. It removes every cross-trial confounder from the comparison - same protocol, same sites, same period - which is far better than comparing against a different trial's arm. It is imprecise, not uninformative.
Does regulatory approval require this evidence?: For fixed-dose combinations of licensed drugs, evidence that each component contributes to the claimed effect is generally expected, and factorial or active-comparator designs are how it is supplied. The strength of that expectation varies by jurisdiction and by indication.
Can a meta-analysis substitute for component arms?: Only by indirect comparison, which requires assuming trials are exchangeable and is weaker than randomising within one trial. Where the within-trial arms exist, they are the better evidence.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum